Oral Anticoagulation in Hemodialysis

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 132 participants.

Also called NCT03799822

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose prevention
Phase
Phase 4
Enrolled
  • 132 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03799822
Other papers using this trial's data
  • Safety and Efficacy of Vitamin K Antagonists versus Rivaroxaban in Hemodialysis Patients with Atrial Fibrillation: A Multicenter Randomized Controlled Trial Journal of the American Society of Nephrology : JASN, 2021-06-01 DOI, PubMed 33753537, PMC8259651 Not in the PMC Open Access subset.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Belgium (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03799822. Randomized; no masking; primary purpose prevention. Start 2017-05-01 (actual); primary completion 2020-09-15 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Oral Anticoagulation in Hemodialysis
Intervention (Drug)
Rivaroxaban 10 MG Oral Tablet
Intervention (Dietary supplement)
MK-7 2000µg thrice weekly
Intervention (Drug)
Vitamin K Antagonist - Drug
Lead sponsor
Onze Lieve Vrouw Hospital (class: other)

Record details

Record id
cardio:ct-nct03799822
Content hash
aef77e121933188f92e793aee6371c0529f7472003f98c0cb427937db31e80bf